Progression of diabetic nephropathy enhances the plasma osteopontin level in type 2 diabetic patients

Endocrine Journal

Volumn 51, Issue 5, 2004, Pages 499-504

  Yamaguchi, Hiroshi ^a   Igarashi, Masahiko ^a   Hirata, Akihiko ^a   Tsuchiya, Hiromi ^a   Sugiyama, Kazuhiko ^b   Morita, Yoshihiro ^b   Jimbu, Yumi ^a   Ohnuma, Hiroshi ^a   Daimon, Makoto ^a   Tominaga, Makoto ^a   Kato, Takeo ^a  

^a YAMAGATA UNIVERSITY   (Japan)

^b Saiseikai Yamagata Hospital   (Japan)

Author keywords

Aging; Diabetes mellitus; Diabetic nephropathy; Osteopontin

Indexed keywords

HEMOGLOBIN A1C; OSTEOPONTIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC NEPHROPATHY; DISEASE COURSE; FEMALE; HUMAN; KIDNEY FAILURE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL;

AGED; AGING; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPONTIN; PREDICTIVE VALUE OF TESTS; SIALOGLYCOPROTEINS;

EID: 8844264544     PISSN: 09188959     EISSN: None     Source Type: Journal    
DOI: 10.1507/endocrj.51.499     Document Type: Article

References (33)

1. Butler WT (1989) The nature and significance of osteopontin. Connect Tissue Res 23: 123-136.
2. Barry ST, Ludbrook SB, Murrison E, Horgan CM (2000) Analysis of the α4β1 integrin-osteopontin interaction. Exp Cell Res 258: 342-351.
3. Chiba S, Rashid MM, Okamoto H, Shiraiwa H, Kon S, Maeda M, Murakami M, Inobe M, Kitabatake A, Chambers AF, Ueda T (2000) The role of osteopontin in the development of granulomatous lesions in lung. Microbiol Immunol 44: 319-332.
4. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, Rittling SR, Denhardt DT, Glimcher MJ, Cantor H (2000) Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity. Science 287: 860-864.
5. Pichler RH, Franceschini N, Young BA, Hugo C, Andoh TF, Burdmann EA, Shankland SJ, Alpers CE, Bennett WM, Couser WG, et al. (1995) Pathogenesis of cyclosporine nephropathy: Role of angiotensin II and osteopontin. J Am Soc Nephrol 6: 1186-1196.
6. Canver CC, Gregory RD, Cooler SD, Voytovich MC (2000) Association of osteopontin with calcification in human mitral valves. J Cardiovasc Surg 41: 171-174.
7. Scott JA, Weir ML, Wilson SM, Xuan JW, Chambers AF, McCormick DG (1998) Osteopontin inhibits inducible nitric oxide synthase activity in rat vascular tissue. Am J Physiol 275: 2258-2265.
8. Wada T, McKee MD, Steitz S, Giachelli CM (1999) Calcification of vascular smooth muscle cell cultures: Inhibition by osteopontin. Circ Res 84: 166-178.
9. Isoda K, Nishikawa K, Kamezawa Y, Yoshida M, Kusahara M, Moroi M, Tada N, Ohsuzu F (2002) Osteopontin plays and important role in the development of medial thickening and neointimal formation. Circ Res 91: 77-82.
10. Li G, Oparil S, Kelpke SS, Chen YF, Thompson JA (2002) Fibroblast growth factor receptor-1 signaling induces osteopontin expression and vascular smooth muscle cell-dependent adventitial fibroblast migration in vivo. Circulation 106: 854-859.
11. Chen NX, O'Neill KD, Duan D, Moe SM (2002) Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int 62: 1724-1731.
12. Takemoto M, Yokote K, Nishimura M, Shigematsu T, Hasegawa T, Kon S, Ueda T, Matsumoto T, Saito Y, Mori S (2000) Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis. Arterioscler Thromb Vasc Biol 20: 624-628.
13. Sodhi CP, Phadke SA, Batlle D, Sahai A (2001) Hypoxia and high glucose cause exaggerated mesangial cell growth and collagen synthesis: Role of osteopontin. Am J Physiol Renal Physiol 280: F667-F674.
14. Bidder M, Shao JS, Charlton-Kachigian N, Loewy AP, Semenkovich CF, Towler DA (2002) Osteopontin transcription in aortic vascular smooth muscle cells is controlled by glucose-regulated upstream stimulatory factor and activator protein-1 activities. J Biol Chem 277: 44485-44496.
15. Kim JH, Skates SJ, Ueda T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC (2002) Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 287: 1671-1679.
16. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med 329: 977-986.
17. American Diabetes Association (2002) Diabetic nephropathy. Diabetes Care 25 (Suppl 1): S85-S98.
18. Shijubo N, Ueda T, Kon S, Maeda M, Segawa T, Imada A, Hirasawa M, Abe S (1999) Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med 160: 1269-1273.
19. Kaimori JY, Takenaka M, Nagasawa Y, Nakajima Y, Izumi M, Akagi Y, Imai E, Hori M (2002) Quantitative analyses of osteopontin mRNA expression in human proximal tubules isolated from renal biopsy tissue sections of minimal change nephrotic syndrome and IgA glomerulonephropathy patients. Am J Kidney Dis 39: 948-957.
20. Fischer JW, Tschøpe C, Reinecke A, Giachelli CM, Unger T (1998) Upregulation of osteopontin expression in renal cortex of streptozotocin-induced diabetic rats is mediated by bradykinin. Diabetes 47: 1512-1518.
21. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Eng J Med 345: 861-869.
22. Tajima T, Okuhara K, Satoh K, Nakase J, Fujieda K (2003) Two novel aquaporin-2 mutations in a sporadic Japanese patients with autosomal recessive nephrogenic diabetes insipidus. Endocr J 50: 473-476.
23. Moe SM, O'Neil KD, Duan D, Ahmed S, Chen NX, Leapman SB, Fineberg N, Kopecky K (2002) Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 61: 638-647.
24. Yu XQ, Fan JM, Nikolic-Paterson DJ, Yang N, Mu W, Pichler R, Johnson RJ, Atkins RC, Lan HY (1999) IL-1 up-regulates osteopontin expression in experimental crescentric glomerulonephritis in the rat. Am J Pathol 154: 833-841.
25. Hudkins KL, Giachelli CM, Eitner F, Couser WG, Johnson RJ, Alpers CE (2000) Osteopontin expression in human crescentric glomerulonephritis. Kidney Int 57: 105-116.
26. Okada H, Moriwaki K, Konishi K, Kobayashi T, Sugahara S, Nakamoto H, Saruta T, Suzuki H (2000) Tubular osteopontin expression in human glomerulonephritis and renal vasculitis. Am J Kidney Dis 36: 498-506.
27. Sano N, Kitazawa K, Sugisaki T (2001) Localization and roles of CD44, hyaluronic acid and osteopontin in IgA nephropathy. Nephron 89: 416-421.
28. Takagi H, Suzuma K, Otani A, Oh H, Koyama S, Ohashi H, Watanabe D, Ojima T, Suganami E, Honda Y (2002) Role of vitronectin receptor-type integrins and osteopontin in ischemic-induced retinal neovascularization. Jpn J Ophthalmol 46: 270-278.
29. Chabas D, Baranzini SE, Mitchell D, Bernard CC, Rittling SR, Denhardt DT, Sobel RA, Lock C, Karpuj M, Pedotti R, Heller R, Oksenberg JR, Steinman L (2001) The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294: 1731-1735.
30. Speer MY, McKee MD, Guldberg RE, Liaw L, Yang HY, Tung E, Karsenty G, Giachelli CM (2002) Inactivation of the osteopontin gene enhances vascular calcification of matrix G1a protein-deficient mice: Evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. J Exp Med 196: 1047-1055.
31. Yamagishi S, Fijimori H, Yonekura H, Tanaka NJ Yamamoto H (1999) Advanced glycation endproducts accelerate in microvascular pericytes. Biochem Biophys Res Commun 258: 353-357.
32. Endlich N, Sunohara M, Nietfeld W, Wolski EW, Schiwek D, Krånzlin B, Gretz N, Kriz W, Eickhoff H, Endlich K (2002) Analysis of differential gene expression in stretched podocytes: Osteopontin enhances adaptation of podocytes to mechanical stress. FASEB J 16: 1850-1852.
33. Takemoto M, Kitahara M, Yokote K, Asaumi S, Take A, Saito Y, Mori S (2001) NK-104, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, reduces osteopontin expression by rat aortic smooth muscle cells. Br J Pharmacol 133: 83-88.